BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22807514)

  • 1. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
    Albiges L; Molinie V; Escudier B
    Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
    Bellmunt J; Dutcher J
    Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
    Pal SK; Figlin RA
    Target Oncol; 2011 Mar; 6(1):5-16. PubMed ID: 21484496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
    Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH; Molina AM; Motzer RJ
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
    Ahrens M; Scheich S; Hartmann A; Bergmann L;
    Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
    Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P; Hoch B; Chevreau C; Joly F; Laguerre B; Lokiec F; Duclos B
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors.
    Choueiri TK; Je Y; Sonpavde G; Richards CJ; Galsky MD; Nguyen PL; Schutz F; Heng DY; Kaymakcalan MD
    Ann Oncol; 2013 Aug; 24(8):2092-7. PubMed ID: 23658373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.